Related Experiment Video
Updated: Aug 19, 2026
Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies
Published on: September 15, 2016
The clinical correlates of IgM M-components: an analysis of thirty-four patients
Abstract:
Thirty-four patients with an IgM M-component were evaluated for clinical presentation and course, laboratory data, and histologic findings. An attempt was made to ignore the presence of the IgM M-component and to assign each patient to one of the following categories: Waldenstrom's macroglobulinemia, IgM myeloma, Hodgkin's disease, lymphoma, chronic lymphocytic leukemia, chronic lymphosarcoma cell leukemia, and IgM M-components not associated with an identifiable lymphoproliferative disorder ("benign" M-component). Although transitional forms occasionally occurred, most patients could be readily categorized. The patients with lymphoma, Hodgkin's disease, chronic lymphocytic leukemia, and chronic lymphosarcoma cell leukemia did not appear to behave differently from patients with these disorders who did not have serum IgM M-component. Both for descriptive convenience and for clinical management, continued attempts should be made to separate patients with IgM M-components according to their underlying conditions.
Insights
Patients with IgM M-component were categorized based on underlying conditions, not the M-component itself. This distinction is crucial for accurate diagnosis and effective clinical management of lymphoproliferative disorders.
Area of Science:
- Hematology
- Oncology
Background:
- Immunoglobulin M (IgM) M-components can be associated with various lymphoproliferative disorders.
- Distinguishing the underlying cause of IgM M-components is critical for patient management.
Purpose of the Study:
- To evaluate clinical presentation, laboratory data, and histologic findings in patients with IgM M-components.
- To determine if the presence of an IgM M-component alters the behavior of specific lymphoproliferative disorders.
Main Methods:
- Retrospective analysis of 34 patients with IgM M-components.
- Categorization of patients into Waldenstrom's macroglobulinemia, IgM myeloma, lymphomas, leukemias, or "benign" M-components, independent of the M-component presence.
- Comparison of disease course between patients with and without IgM M-components within specific diagnostic categories.
Main Results:
- Most patients with IgM M-components could be readily categorized into distinct underlying conditions.
- Patients with lymphoma, Hodgkin's disease, chronic lymphocytic leukemia, and chronic lymphosarcoma cell leukemia with IgM M-components did not exhibit different clinical behavior compared to those without.
Conclusions:
- The presence of an IgM M-component does not fundamentally alter the clinical course of associated lymphoproliferative disorders.
- Continued efforts to classify patients based on their underlying condition, rather than solely on the IgM M-component, are essential for accurate diagnosis and management.
